SANOFI

A LEADER IN SPECIALITY CARE

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases,multiple sclerosis, oncology and immunology. We help people with debilating and complex conditions that are often difficult to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.

Our ambition is to be the industry leader in specialty care. We currently provide more than 20 treatments to patients globally, with many potential new therapies being studied in clinical trials and in Sanofi laboratories.

BUILDING ON A STRONG LEGACY

Our approach is shaped by a long history of developing highly specialized treatments and foring close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, we rapidly grew to become one of the world's leading biotechnology companies, recognized for our pioneering development of treatments for rare genetic disorders and our innovative contributions to medical science and biomanufacturing.

Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofi's programs in oncology and immunology.

Inspired by the potential to improve patients' lives, more than 3,000 Sanofi Genzyme employees work at the forefront of health care and biotechnology, supported by thousands of Sanofi colleagues around the world.

www.sanofi.fr